Kidney and metabolic disorders
HBM contact: Dr Ulrich Geilinger
Company status: public
Allena Pharmaceuticals, USA, is late-stage clinical biopharma company developing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. Allena’s lead product candidate, ALLN-177, is a first in class, oral enzyme therapeutic for the treatment of patients with hyperoxaluria, the main cause of kidney stones.